BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -51.90M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 28.13M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-51.90M | (m) | (m) | $28.13M | (m) | (m) |
| 2026-03-31 | $-53.27M | (m) | (m) | $30.05M | (m) | (m) |
| 2025-12-31 | $12.52M | (m) | (m) | $33.56M | (m) | (m) |
| 2025-09-30 | $11.86M | (m) | (m) | $39.56M | (m) | (m) |
| 2025-06-30 | $4.71M | (m) | (m) | $45.04M | (m) | (m) |
| 2025-03-31 | $-4.00M | (m) | (m) | $48.27M | (m) | (m) |
| 2024-12-31 | $-78.78M | (m) | (m) | $51.31M | (m) | (m) |
| 2024-09-30 | $-81.36M | (m) | (m) | $54.30M | (m) | (m) |
| 2024-06-30 | $-87.24M | (m) | (m) | $57.54M | (m) | (m) |
| 2024-03-31 | $-85.14M | (m) | (m) | $58.14M | (m) | (m) |
| 2023-12-31 | $-86.46M | (m) | (m) | $59.35M | (m) | (m) |
| 2023-09-30 | $-87.46M | (m) | (m) | $58.67M | (m) | (m) |
| 2023-06-30 | $-85.57M | (m) | (m) | $58.36M | (m) | (m) |
| 2023-03-31 | $-88.71M | (m) | (m) | $61.40M | (m) | (m) |
| 2022-12-31 | $-92.83M | (m) | (m) | $64.44M | (m) | (m) |
| 2022-09-30 | $-97.06M | (m) | (m) | $69.49M | (m) | (m) |
| 2022-06-30 | $-110.30M | (m) | (m) | $81.27M | (m) | (m) |
| 2022-03-31 | $-121.84M | (m) | (m) | $91.80M | (m) | (m) |
| 2021-12-31 | $-126.87M | (m) | (m) | $96.83M | (m) | (m) |
| 2021-09-30 | $-123.97M | (m) | (m) | $94.92M | (m) | (m) |
| 2021-06-30 | $-107.09M | (m) | (m) | $80.22M | (m) | (m) |
| 2021-03-31 | $-87.40M | (m) | (m) | $63.67M | (m) | (m) |
| 2020-12-31 | $-69.57M | $0.00 | (m) | $48.21M | (m) | (m) |
| 2020-09-30 | $-56.73M | (m) | (m) | $37.91M | (m) | (m) |
| 2020-06-30 | $-46.40M | (m) | (m) | $30.62M | (m) | (m) |
| 2020-03-31 | $-38.37M | (m) | (m) | $26.09M | (m) | (m) |
| 2019-12-31 | $-29.33M | $0.00 | (m) | $21.75M | (m) | (m) |
| 2019-09-30 | $-22.03M | $0.00 | (m) | (m) | (m) | (m) |
| 2019-06-30 | $-16.23M | $0.00 | (m) | (m) | (m) | (m) |
| 2019-03-31 | $-11.14M | $0.00 | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-8.90M | $0.00 | (m) | $6.95M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |